Algert Global LLC bought a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 5,865 shares of the biotechnology company's stock, valued at approximately $844,000.
Other institutional investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its holdings in Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after buying an additional 743,815 shares in the last quarter. Vanguard Group Inc. grew its stake in Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after purchasing an additional 56,723 shares during the period. Champlain Investment Partners LLC grew its stake in Repligen by 8.6% in the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock valued at $222,176,000 after purchasing an additional 122,595 shares during the period. Alliancebernstein L.P. grew its stake in Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock valued at $145,508,000 after purchasing an additional 191,439 shares during the period. Finally, Conestoga Capital Advisors LLC grew its stake in Repligen by 0.7% in the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock valued at $136,395,000 after purchasing an additional 6,872 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.
Repligen Price Performance
Shares of Repligen stock traded down $2.17 during trading on Tuesday, reaching $131.55. 546,924 shares of the stock traded hands, compared to its average volume of 729,574. The company has a market capitalization of $7.39 billion, a price-to-earnings ratio of -257.94, a P/E/G ratio of 4.54 and a beta of 1.21. The business has a fifty day simple moving average of $134.55 and a two-hundred day simple moving average of $145.43. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a 52-week low of $102.97 and a 52-week high of $182.52.
Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same quarter last year, the business posted $0.28 earnings per share. The business's quarterly revenue was up 10.4% compared to the same quarter last year. Sell-side analysts expect that Repligen Co. will post 1.72 EPS for the current year.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on RGEN shares. TD Cowen assumed coverage on Repligen in a report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective on the stock. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. HC Wainwright restated a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Royal Bank of Canada reduced their price target on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Finally, Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a research report on Tuesday, April 29th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $173.25.
Get Our Latest Stock Report on RGEN
Insider Activity at Repligen
In other Repligen news, Director Margaret Pax purchased 250 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is owned by insiders.
Repligen Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
